Invercaria and la Caixa back nLife

Invercaria invested €2.5m through the Jeremie Capital Riesgo fund while La Caixa provided the remaining €2.5m via Caixa Capital Risc and Caixa Capital Biomed.

The investment will underpin clinical trials and human subject research.

Company
Founded in 2009, n-Life develops nucleic acids therapeutics programs for major depressive disorder, oncology, obesity and a universal influenza DNA vaccine. The company is a joint venture owned by technology platform Dendrico, a Cross Road Biotech portfolio company, and biotechnology firm Nedken Solutions.

People
Laura Gómiz is CEO of Invercaria.

Advisers
Equity - Fornesa, Prada y Fernandez (Legal); PwC (Financial due diligence); Sterne, Kessler, Goldstein & Fox (Intellectual property due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain
• Caixa Capital Risc